Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the TD Cowen 45th Annual Health Care Conference on March 3, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1][2] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3] - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] - Supernus is also developing a range of novel CNS product candidates targeting epilepsy, depression, and other CNS disorders [4]